2025-10-24 - Analysis Report
Okay, here's the analysis of Teladoc Health Inc. (TDOC), incorporating the provided data.

**TDOC: Teladoc Health Inc. Analysis**

Teladoc Health Inc. is a telehealth and virtual healthcare company offering a range of services, including virtual medical consultations.

**1. Performance vs. S&P 500 (VOO)**

*   **TDOC Cumulative Return:** -58.47%
*   **VOO Cumulative Return:** 100.13%
*   **Absolute Divergence:** -158.6%
*   **Divergence Range:** (max: 312.6, min: -162.5)
*   **Relative Divergence:** 1.1

TDOC has significantly underperformed the S&P 500, with a substantial negative cumulative return. The relative divergence of 1.1 suggests the current divergence is near the lower end of its historical range compared to VOO.

**Alpha, Beta Analysis**

| Year       | CAGR     | MDD  | Alpha  | Beta  | Cap(B) |
|------------|----------|------|--------|-------|--------|
| 2015-2017  | 75.0%    | 79.8% | 49.0%  | -0.1  | 6.1    |
| 2016-2018  | 103.0%   | 69.4% | 87.0%  | -0.1  | 8.7    |
| 2017-2019  | 140.0%   | 73.7% | 118.0% | 0.4  | 14.7   |
| 2018-2020  | 104.0%   | 80.8% | 81.0%  | 0.3  | 35.1   |
| 2019-2021  | -77.0%   | 80.8% | -124.0% | 0.3  | 16.1   |
| 2020-2022  | -249.0%  | 85.9% | -249.0% | -0.7  | 4.2    |
| 2021-2023  | -312.0%  | 85.9% | -314.0% | -1.5  | 3.8    |
| 2022-2024  | -92.0%   | 85.9% | -112.0% | -1.6  | 1.6    |
| 2023-2025  | -29.0%   | 81.6% | -93.0%  | -0.8  | 1.5    |

*   **CAGR:**  The CAGR (Compound Annual Growth Rate) shows a significant decline in recent years, turning negative.
*   **MDD:**  High Maximum Drawdown (MDD) values indicate substantial potential losses.
*   **Alpha:**  Consistently negative Alpha values in recent years suggest underperformance relative to the benchmark.
*   **Beta:**  Beta values have fluctuated, becoming increasingly negative, indicating a potential inverse correlation with the market.
*   **Cap(B):** Market capitalization has decreased significantly, particularly in recent years.

**2. Recent Price Action**

*   **Current Price:** $8.66
*   **Last Market Data:** Price: $8.6, Previous Close: $8.34, Change: +3.12% (Indicates a recent upward movement)
*   **5-day Moving Average:** 8.826
*   **20-day Moving Average:** 8.4407
*   **60-day Moving Average:** 7.8354

The price is above the 20-day and 60-day moving averages but below the 5-day moving average. The recent 3.12% increase suggests short-term positive momentum.

**3. Market Risk Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.9 (Medium Investment Recommendation)
*   **RSI:** 57.24 (Neutral, neither overbought nor oversold)
*   **PPO:** 0.1417 (Positive, indicating potential upward momentum)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (110 shares - Very Safe)
*   **Recent (20-day) Relative Divergence Change:** -0.2 (Short-term decline in divergence)
*   **Expected Return:** -8697.7% (Extremely negative, suggesting significant long-term underperformance relative to the S&P 500)
*   **Recent Market Change:** {'price': 8.6, 'previousClose': 8.34, 'change': 3.12} indicates a recent price increase (potential bounce).

The MRI suggests a medium investment risk, but the extremely negative expected return is a major concern. The Hybrid Signal recommends buying.

**4. Recent News & Significant Events**

*   **CFO Transition:** A change in CFO can introduce uncertainty.
*   **Earnings Expectations:** Mixed signals – some sources expect earnings to beat estimates, while others focus on valuation concerns.
*   **Stock Performance:**  Articles indicate underperformance compared to market gains.

**4-2. Analyst Opinions**

*   **Consensus:** Hold
*   **Mean Rating:** 2.64 (~Hold)
*   **Target Price:** Average $9.22 (suggests slight upside), High $12.00, Low $7.00.
*   **Recent Rating Changes:** No recent rating changes are available.

Analyst ratings are neutral, with a slight potential upside based on the average target price.

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 매출     |
|------------|-------|----------|
| 2025-07-30 | -0.19 | 0.63 B$ |
| 2025-05-01 | -0.53 | 0.63 B$ |
| 2024-10-31 | -0.19 | 0.64 B$ |
| 2024-08-01 | -4.92 | 0.64 B$ |
| 2025-07-30 | -4.92 | 0.64 B$ |

*   **EPS:** EPS (Earnings Per Share) has been consistently negative except for the last two quarters of 2025.
*   **Revenue:** Revenue has remained relatively stable around $0.63-0.64 billion.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-06-30 | $0.63B  | 69.85%        |
| 2025-03-31 | $0.63B  | 68.73%        |
| 2024-12-31 | $0.64B  | 70.50%        |
| 2024-09-30 | $0.64B  | 71.94%        |
| 2024-06-30 | $0.64B  | 70.73%        |

**Capital and Profitability:**

| Quarter    | Equity  | ROE       |
|------------|---------|-----------|
| 2025-06-30 | $1.42B  | -2.30%    |
| 2025-03-31 | $1.43B  | -6.52%    |
| 2024-12-31 | $1.49B  | -3.25%    |
| 2024-09-30 | $1.51B  | -2.21%    |
| 2024-06-30 | $1.50B  | -55.77%   |

*   **Revenue:** Stable revenue around $0.63-0.64B.
*   **Profit Margin:** Consistently high profit margins.
*   **Equity:** Equity has slightly decreased over the past year.
*   **ROE:** ROE (Return on Equity) has been negative, indicating poor profitability.

**7. Summary Analysis**

Teladoc Health (TDOC) presents a mixed picture. The company has experienced a significant underperformance relative to the S&P 500, with a concerningly negative expected return. Historical Alpha values are negative, and recent earnings reports show negative EPS, though revenue has been relatively stable. While profit margins are high, negative ROE indicates that the company is not generating profits effectively from its equity.

Recent price action shows a slight upward movement, and the RSI is neutral. Analyst ratings are Hold, with a potential upside based on the average target price. Recent news includes a CFO transition and mixed opinions on earnings potential.

**Overall:**  TDOC is a high-risk investment. While there are some positive indicators, such as high profit margins and a recent price increase, the negative expected return and underperformance relative to the market are major concerns. Investors should carefully consider their risk tolerance and conduct further due diligence before investing in TDOC.
